Skip to content

Study · Randomized controlled trial · n = 203 · 2006

5 results

Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial.

Lambalk CB, Leader A, Olivennes F, Fluker MR, Andersen AN, Ingerslev J, Khalaf Y, Avril C, Belaisch-Allart J, Roulier R, Mannaerts B

Human reproduction (Oxford, England)16 Dec 2005Cited by 71 (Europe PMC)

PMID16361296 (opens in a new tab)DOI10.1093/humrep/dei386 (opens in a new tab)PepBankPUB-16361296
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women undergoing stimulated IUI, premature LH rises occurred in 3.9% with ganirelix versus 28.0% with placebo (P=0.003).

    In plain wordsIn women undergoing stimulated IUI, premature LH rises occurred in 3.9% with ganirelix versus 28.0% with placebo.

    Peptide
    Ganirelix
    Outcome
    DecreasePremature LH rise, ITT
    Study

    n = 203

    Comparator
    placebo
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/dayAs given in this study (human).

    Measurements

    LH rise incidence
    3.9%
    ganirelix
    LH rise incidence
    28%
    placebo

    Source sentences

    Summary
    The incidence of LH rises was significantly lower in ganirelix cycles compared to placebo cycles (3.9 versus 28.0%; P=0.003 for ITT analysis).
    4 context sentences
    Summary · context
    In the ganirelix group, four subjects had a premature LH rise (value>or=10 IU/l), one LH rise prior to the start of ganirelix and three LH rises during ganirelix treatment, whereas in the placebo group 28 subjects had a premature LH rise, six subjects prior to the start of placebo and 22 subjects du…
    Summary · context
    Women of infertile couples, diagnosed with unexplained or male factor infertility, were randomized to receive either ganirelix (n=103) or placebo (n=100) in a double-blind design.
    Summary · context
    All women were treated with an individualized, low-dose rFSH regimen started on day 2-3 of cycle.
    Summary · context
    Ganirelix (0.25 mg/day) was started if one or more follicles>or=14 mm were visualized.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women undergoing stimulated IUI, premature luteinization occurred in one ganirelix recipient versus 17 placebo recipients.

    In plain wordsIn women undergoing stimulated IUI, premature luteinization occurred in one ganirelix recipient versus 17 placebo recipients.

    Peptide
    Ganirelix
    Outcome
    DecreasePremature luteinization
    Study

    n = 203

    Comparator
    placebo
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/dayAs given in this study (human).

    Measurements

    Subjects with premature luteinization
    1 subjects
    ganirelix
    Subjects with premature luteinization
    17 subjects
    placebo

    Source sentences

    Summary
    Premature luteinization (LH rise with concomitant progesterone rise>or=1 ng/ml) was observed in one subject in the ganirelix group and in 17 subjects in the placebo group of which three subjects had a premature spontaneous ovulation.
    3 context sentences
    Summary · context
    Women of infertile couples, diagnosed with unexplained or male factor infertility, were randomized to receive either ganirelix (n=103) or placebo (n=100) in a double-blind design.
    Summary · context
    All women were treated with an individualized, low-dose rFSH regimen started on day 2-3 of cycle.
    Summary · context
    Ganirelix (0.25 mg/day) was started if one or more follicles>or=14 mm were visualized.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In stimulated IUI, three subjects had premature LH rises during ganirelix treatment versus 22 during placebo treatment.

    In plain wordsIn stimulated IUI, three subjects had premature LH rises during ganirelix treatment versus 22 during placebo treatment.

    Peptide
    Ganirelix
    Outcome
    DecreasePremature LH rise during treatment
    Study

    n: not reported in source

    Comparator
    placebo
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/dayAs given in this study (human).

    Measurements

    Subjects with premature LH rise during treatment
    3 subjects
    ganirelix
    Subjects with premature LH rise during treatment
    22 subjects
    placebo

    Source sentences

    Summary
    In the ganirelix group, four subjects had a premature LH rise (value>or=10 IU/l), one LH rise prior to the start of ganirelix and three LH rises during ganirelix treatment, whereas in the placebo group 28 subjects had a premature LH rise, six subjects prior to the start of placebo and 22 subjects du…
    3 context sentences
    Summary · context
    Women of infertile couples, diagnosed with unexplained or male factor infertility, were randomized to receive either ganirelix (n=103) or placebo (n=100) in a double-blind design.
    Summary · context
    All women were treated with an individualized, low-dose rFSH regimen started on day 2-3 of cycle.
    Summary · context
    Ganirelix (0.25 mg/day) was started if one or more follicles>or=14 mm were visualized.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In stimulated IUI, LH rises occurred in 2.9% with ganirelix versus 23.4% with placebo after exclusion of elevated pretreatment LH (P=0.003).

    In plain wordsIn stimulated IUI, LH rises occurred in 2.9% with ganirelix versus 23.4% with placebo after exclusion of elevated pretreatment LH.

    Peptide
    Ganirelix
    Outcome
    DecreasePremature LH rise excluding elevated pretreatment LH
    Study

    n: not reported in source

    Comparator
    placebo
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/dayAs given in this study (human).

    Measurements

    LH rise incidence excluding elevated pretreatment LH
    2.9%
    ganirelix
    LH rise incidence excluding elevated pretreatment LH
    23.4%
    placebo

    Source sentences

    Summary
    When excluding subjects with an LH value>or=10 IU/l before the start of ganirelix/placebo the incidence of LH rises was also significantly lower in ganirelix cycles compared to placebo cycles (2.9 versus 23.4%; P=0.003 for ITT analysis).
    3 context sentences
    Summary · context
    Women of infertile couples, diagnosed with unexplained or male factor infertility, were randomized to receive either ganirelix (n=103) or placebo (n=100) in a double-blind design.
    Summary · context
    All women were treated with an individualized, low-dose rFSH regimen started on day 2-3 of cycle.
    Summary · context
    Ganirelix (0.25 mg/day) was started if one or more follicles>or=14 mm were visualized.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women undergoing stimulated IUI, ongoing pregnancy rates per attempt were 12.6% with ganirelix and 12.0% with placebo.

    In plain wordsIn women undergoing stimulated IUI, ongoing pregnancy rates per attempt were 12.6% with ganirelix and 12.0% with placebo.

    Peptide
    Ganirelix
    Outcome
    Direction not reportedOngoing pregnancy per attempt
    Study

    n = 203

    Comparator
    placebo
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    0.25 mg/dayAs given in this study (human).

    Measurements

    Ongoing pregnancy rate per attempt
    12.6%
    ganirelix
    Ongoing pregnancy rate per attempt
    12%
    placebo

    Source sentences

    Summary
    Ongoing pregnancy rates per attempt were 12.6 and 12.0% for the ganirelix and placebo groups respectively.
    3 context sentences
    Summary · context
    Women of infertile couples, diagnosed with unexplained or male factor infertility, were randomized to receive either ganirelix (n=103) or placebo (n=100) in a double-blind design.
    Summary · context
    All women were treated with an individualized, low-dose rFSH regimen started on day 2-3 of cycle.
    Summary · context
    Ganirelix (0.25 mg/day) was started if one or more follicles>or=14 mm were visualized.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.